(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 September 2015 (24.09.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/143246 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2015/021608

(22) International Filing Date:
19 March 2015 (19.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/955,705 19 March 2014 (19.03.2014) US
61/982,131 21 April 2014 (21.04.2014) US

(71) Applicant: **ISIS PHARMACEUTICALS, INC.** [US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **FREIER, Susan, M.**; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **HUNG, Gene**; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **BENNETT, C., Frank**; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(74) Agents: **SCARR, Rebecca** et al.; McNeill Baur PLLC, 125 Cambridge Park Dr, Suite 301, Cambridge, MA 02140 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2015/143246 A1

(54) Title: COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION

(57) Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.